Single administration vaccines: delivery challenges, in vivo performance, and translational considerations

Abstract

Introduction With a limited global supply of vaccines and an increasing vaccine hesitancy, improving vaccination coverage has become a priority. Current vaccination regimes require multiple doses to be administered in a defined schedule where missed doses may lead to incomplete vaccine coverage and failure of immunization programmes. As such, there is an ever-increasing demand to convert multi-dose injectable vaccines into single-dose formats, often called single administration vaccines (SAVs). Areas covered This review summarizes recent developments in the field of SAVs, with a focus on pulsatile or controlled-release formulations. It will identify the technical challenges, translational as well as commercial barriers to SAVs development. Furthermore, the progress of SAV formulations for hepatitis B and polio vaccines will be reviewed thoroughly as case studies, with a focus on the development challenges and the preclinical immunogenicity/reactogenicity data. Expert opinion Despite the efforts to develop SAVs, few attempts have advanced to Phase-I trials. Considering the SAV development journey and bottlenecks, including commercial barriers from the early stages, may overcome some of the hurdles around the technology. The renewed global focus on vaccines since the COVID-19 pandemic could facilitate development of a new generation of technologies for pandemic preparedness including strategies for SAVs.

Publication DOI: https://doi.org/10.1080/14760584.2023.2229431
Divisions: College of Health & Life Sciences > Aston Pharmacy School
College of Health & Life Sciences
College of Health & Life Sciences > Chronic and Communicable Conditions
Aston University (General)
Funding Information: This work was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) and Aston University funded Midlands Integrative Biosciences Training Partnership (MIBTP) (BB/T00746X/1).
Additional Information: Copyright © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Uncontrolled Keywords: Hepatitis B vaccine,PLGA,Single administration vaccines,commercialization,microsphere formulation,multiple dose vaccine,vaccine controlled release,vaccine stability,Drug Discovery,Molecular Medicine,Pharmacology,Immunology
Publication ISSN: 1744-8395
Last Modified: 04 Nov 2024 09:23
Date Deposited: 14 Jul 2023 08:39
Full Text Link:
Related URLs: https://www.tan ... 84.2023.2229431 (Publisher URL)
http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Review article
Published Date: 2023-12-31
Published Online Date: 2023-07-04
Accepted Date: 2023-06-21
Submitted Date: 2023-04-05
Authors: Michaelides, Kyprianos
Prasanna, Maruthi
Badhan, Raj (ORCID Profile 0000-0002-0904-9324)
Mohammed, Afzal-Ur-Rahman (ORCID Profile 0000-0002-5212-3040)
Walters, Adam
Howard, M. Keith
Dulal, Pawan
Al-Khattawi, Ali

Download

[img]

Version: Published Version

License: Creative Commons Attribution

| Preview

Export / Share Citation


Statistics

Additional statistics for this record